2060610-53-7

JBJ-04-125-02 (50 mg/kg; oral gavage; once daily; for 15 weeks; EGFR^{L858R/T790M/C797S} genetically engineered mice) treatment leads to marked tumor regressions within 4 weeks of treatment^[1].
JBJ-04-125-02 exhibits a moderate half-life of 3 hours and a high area under curve of 728,577 min?ng/mL (AUClast) following 3 mg/kg intravenous (i.v.) dose. A 20 mg/kg oral dose of JBJ-04-125-02 achieves an average maximal plasma concentration of 1.1 μmol/L with an oral bioavailability of 3%^[1].